dacarbazine and Ph 1 Chromosome

dacarbazine has been researched along with Ph 1 Chromosome in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Champlin, R; Cortes, J; Estrov, Z; Garcia-Manero, G; Garris, R; Huang, X; Jabbour, E; Jacob, J; Jain, N; Kadia, T; Kantarjian, H; Kebriaei, P; Khouri, MR; Konopleva, M; Marin, D; O'Brien, S; Patel, Y; Ravandi, F; Rytting, M; Sasaki, K; Short, NJ; Takahashi, K; Thomas, D	1
Frey, N; Goldstein, S; Hexner, EO; Landsburg, DJ; Loren, A; Luger, S; Nasta, SD; Perl, AE; Porter, DL; Stadtmauer, E; Tsai, DE	1

Trials

2 trial(s) available for dacarbazine and Ph 1 Chromosome

Article	Year
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial. JAMA oncology, 2018, Feb-01, Volume: 4, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Inotuzumab Ozogamicin; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Survival Analysis; Vincristine; Young Adult	2018
Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens. American journal of hematology, 2013, Volume: 88, Issue:8 Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Cyclophosphamide; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Incidence; Infections; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Vincristine; Vindesine	2013

Article

Year

Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial.

JAMA oncology, 2018, Feb-01, Volume: 4, Issue:2

Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dacarbazine; Dexamethasone; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Female; Hematopoietic Stem Cell Transplantation; Humans; Inotuzumab Ozogamicin; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Recurrence; Salvage Therapy; Survival Analysis; Vincristine; Young Adult

2018

Receipt of maintenance therapy is most predictive of survival in older acute lymphoblastic leukemia patients treated with intensive induction chemotherapy regimens.

American journal of hematology, 2013, Volume: 88, Issue:8

Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cisplatin; Cyclophosphamide; Dacarbazine; Dexamethasone; Disease-Free Survival; Doxorubicin; Female; Humans; Incidence; Infections; Male; Middle Aged; Philadelphia Chromosome; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Predictive Value of Tests; Remission Induction; Retrospective Studies; Risk Factors; Survival Rate; Vincristine; Vindesine

2013